Patients given the medicine, known as vismodegib or GDC- 0449, had fewer basal cell carcinomas than those who received a placebo, according to a statement from the American Association for Cancer Research conference in Orlando, Florida. The size of existing tumors “decreased significantly” for those getting the drug, while carcinomas were “essentially unchanged” for patients who got placebo, researchers said.
The 41 patients in the trial had basal cell nevus syndrome, a disease that leads to a higher risk of skin cancers. Side effects, including loss of taste, muscle cramps and weight loss, caused 20 percent of patients to discontinue the drug.
To contact the reporter on this story: Phil Serafino in Paris at email@example.com.
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org.